Loading stock analysis…
Evidence Synthesis
Last synthesized: 9 Jul 2026, 21:12
Evidence Synthesis
NATCOPHARM's 83.07% is accelerating, up from 10.44%.
The company's .44% is decelerating, down from 34.78%. Revenue growth year-over-year is decelerating, down from -34.1% to -39.6%. The close price is decelerating, down from 984.15 INR to 966.3 INR.
Source observations behind the synthesis narrative.
| Metric | Value | Previous Value | Trend |
|---|---|---|---|
| GROSS_MARGIN | 83.07 % | 10.44 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 10.44 % | 34.78 | ▼ |
| REVENUE_GROWTH_YOY | -39.6 % | -34.1 | ▼ |
| EPS_ACTUAL | 26.84 INR | 28.94 | ▼ |
| EPS_SURPRISE_PERCENT | -0.25 % | 0.179 | ▼ |
| PRICE_CHANGE_PERCENT | -1.814 % | — | - |
| DAILY_VOLUME | 10,59,161 shares | 8,19,369 | ▲ |
| CLOSE_PRICE | 966.3 INR | 984.15 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.3 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 2 count | 3 | ▼ |
| TARGET_PRICE_PREMIUM | 5.68 % | — | - |